CDNA OF JANUSINE--A NOVEL IMMUNOMODULATORY MONOKINE
CDNA OF JANUSINE--A NOVEL IMMUNOMODULATORY MONOKINE
批准号:
3489597
负责人:
JAMES W LARRICK
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-06-01 至 1992-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from applicant's abstract):HIV infected macrophages
release elevated quantities of IL1 and a novel 7kd monokine with
pleiotropic activities: on the one hand it inhibits IL1 and IL6 induced
T lymphocyte comitogenesis, on the other hand it stimulates B cell
mitogenesis. this immunomodulatory monokine is called Janusine because
of its seemingly opposite bioactivities. It is hypothesized that Janusine
plays an important role in the pathogenesis of HIV infection and other
conditions of dysfunctional immunoregulation. The overall goal of the
research is to clone, express, and characterize the activities of
Janusine. In Phase I, the full length cDNA clones of Janusine will
obtained. cDNA libraries will be constructed in lambda gt 11 using mRNA
from LPS stimulated hyamn macrophages or macrophage cell lines and
screened using a neutralizing immunoblot positive anti-Janusine
monoclonal antibody. Bioactive Janusine clones will be identified using
expression in the Okayama-Berg vector transfected into Cos 7 cells. The
Janusine cDNA will be expressed and protein purified for biological
studies. In Phase II, the therapeutic potential of Janusine will be
evaluated. The cloning of Janusine may provide a novel therapeutic for
diseases characterized by uncontrolled inflammation such as rheumatoid
arthritis. Inhibitors of this monokine may benefit AIDS or sepsis
patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
-
批准号:10759808
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2023
-
负责人:JAMES W LARRICK
-
依托单位:
Therapy for ectopic calcification in pseudoxanthoma elasticum
-
批准号:10763057
-
项目类别:
-
资助金额:$28.58万
-
财政年份:2023
-
负责人:JAMES W LARRICK
-
依托单位:
Pan-COVID Therapeutic
-
批准号:10546550
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical
-
批准号:10704207
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Improved carnosic acid congener compounds for Alzheimer’s disease
-
批准号:10601159
-
项目类别:
-
资助金额:$32.62万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Therapeutic antibody for anorexia nervosa
-
批准号:10480127
-
项目类别:
-
资助金额:$25.96万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Therapeutic antibody for hyperemesis gravidarum
-
批准号:10601709
-
项目类别:
-
资助金额:$30.08万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Advancing a novel therapy for preeclampsia
-
批准号:10478384
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2022
-
负责人:JAMES W LARRICK
-
依托单位:
Inhibiting GPR146 in hypercholesterolemia
-
批准号:10255573
-
项目类别:
-
资助金额:$24.97万
-
财政年份:2021
-
负责人:JAMES W LARRICK
-
依托单位:
Therapeutic antibody for cancer-associated cachexia
-
批准号:10244794
-
项目类别:
-
资助金额:$25.23万
-
财政年份:2021
-
负责人:JAMES W LARRICK
-
依托单位:
Novel anti-fibrotic therapy for IPF
-
批准号:9906133
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2020
-
负责人:JAMES W LARRICK
-
依托单位:
Targeting TGF-beta activation in tumors
-
批准号:9907773
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2019
-
负责人:JAMES W LARRICK
-
依托单位:
Novel therapy for Goodpasture syndrome
-
批准号:9458269
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2017
-
负责人:JAMES W LARRICK
-
依托单位:
Novel Aminoadamantane Nitrates for the Treatment of Neurological Diseases
-
批准号:9045917
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:JAMES W LARRICK
-
依托单位:
Novel NMDA Receptor Antagonists for Beta Cell Rescue
-
批准号:9047082
-
项目类别:
-
资助金额:$22.46万
-
财政年份:2015
-
负责人:JAMES W LARRICK
-
依托单位:
Novel therapy for Netherton syndrome
-
批准号:8977549
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:JAMES W LARRICK
-
依托单位:
Novel Therapy for Tumor-induced Osteomalacia
-
批准号:8646263
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering
-
批准号:8978257
-
项目类别:
-
资助金额:$49.98万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Antibody-Membrane Switch (AMS) technology for optimized antibody engineering
-
批准号:9089847
-
项目类别:
-
资助金额:$45.58万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
Point-of-care immunoassay panel for cardiotonic steroids
-
批准号:8779926
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:JAMES W LARRICK
-
依托单位:
海外基金